
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TCRT-ESO-A2
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : PharmaEssentia
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Axis Therapeutics and PharmaEssentia will collaborate to conduct an initial clinical study of Axis Therapeutics’ TCRT-ESO-A2 therapy, targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients, and to manufacture the investigati...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 13, 2020
Lead Product(s) : TCRT-ESO-A2
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : PharmaEssentia
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TCRT-ESO-A2
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : PharmaEssentia
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Axis Therapeutics and PharmaEssentia will collaborate to conduct an initial clinical study of Axis Therapeutics’ TCRT-ESO-A2 therapy, targeting solid tumors that are NY-ESO-1 positive in HLA-A positive patients, and to manufacture the investigational p...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 13, 2020
Lead Product(s) : TCRT-ESO-A2
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : PharmaEssentia
Deal Size : Undisclosed
Deal Type : Collaboration
